These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 34864977)

  • 1. Resilience of individuals with familial hypercholesterolaemia to develop atherosclerotic cardiovascular disease: lessons learned from the elderly.
    Santos RD; Coutinho ER
    Eur J Prev Cardiol; 2022 Sep; 29(12):e309-e311. PubMed ID: 34864977
    [No Abstract]   [Full Text] [Related]  

  • 2. Difficulties in gauging atherosclerotic cardiovascular disease risk heterogeneity in familial hypercholesterolemia.
    Mizuta MH; Santos RD
    Atherosclerosis; 2022 Oct; 358():57-59. PubMed ID: 36049962
    [No Abstract]   [Full Text] [Related]  

  • 3. Cellular senescence, telomeres, and cardiovascular risk in familial hypercholesterolaemia.
    Banach M; Penson PE
    Eur J Prev Cardiol; 2022 May; 29(5):718-720. PubMed ID: 33624078
    [No Abstract]   [Full Text] [Related]  

  • 4. Heterozygous familial hypercholesterolaemia in childhood: cardiovascular risk prevention.
    van der Graaf A; Kastelein JJP; Wiegman A
    J Inherit Metab Dis; 2009 Dec; 32(6):699. PubMed ID: 19898954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High miR-133a levels in the circulation anticipates presentation of clinical events in familial hypercholesterolaemia patients.
    Escate R; Padró T; Suades R; Camino S; Muñiz O; Diaz-Diaz JL; Sionis A; Mata P; Badimon L
    Cardiovasc Res; 2021 Jan; 117(1):109-122. PubMed ID: 32061123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. To be or not to be resilient in familial hypercholesterolaemia: implications for the management.
    Mercuro G; Cadeddu Dessalvi C; Deidda M
    Eur J Prev Cardiol; 2022 May; 29(5):793-794. PubMed ID: 34864958
    [No Abstract]   [Full Text] [Related]  

  • 7. First insights from the EAS familial hypercholesterolaemia collaboration registry: FH is still underdiagnosed and undertreated.
    Stock J
    Atherosclerosis; 2019 Nov; 290():138-139. PubMed ID: 31610884
    [No Abstract]   [Full Text] [Related]  

  • 8. Type 2 diabetes mellitus in heterozygous familial hypercholesterolaemia: the hazardous intersection of cardiometabolic and genetic risk.
    German CA; Shapiro MD
    Eur J Prev Cardiol; 2022 Jan; 28(16):1817-1818. PubMed ID: 33961017
    [No Abstract]   [Full Text] [Related]  

  • 9. Editorial Commentary: What Determines the Risk of Cardiovascular Disease in Familial Hypercholesterolemia?
    Brunham LR; Mancini GBJ
    Trends Cardiovasc Med; 2021 May; 31(4):216-217. PubMed ID: 32407995
    [No Abstract]   [Full Text] [Related]  

  • 10. Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors.
    Pećin I; Hartgers ML; Hovingh GK; Dent R; Reiner Ž
    Eur J Prev Cardiol; 2017 Sep; 24(13):1383-1401. PubMed ID: 28644091
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel.
    Santos RD; Gidding SS; Hegele RA; Cuchel MA; Barter PJ; Watts GF; Baum SJ; Catapano AL; Chapman MJ; Defesche JC; Folco E; Freiberger T; Genest J; Hovingh GK; Harada-Shiba M; Humphries SE; Jackson AS; Mata P; Moriarty PM; Raal FJ; Al-Rasadi K; Ray KK; Reiner Z; Sijbrands EJ; Yamashita S;
    Lancet Diabetes Endocrinol; 2016 Oct; 4(10):850-61. PubMed ID: 27246162
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease in patients with genotyped familial hypercholesterolemia in Norway during 1994-2009, a registry study.
    Mundal L; Veierød MB; Halvorsen T; Holven KB; Ose L; Iversen PO; Tell GS; Leren TP; Retterstøl K
    Eur J Prev Cardiol; 2016 Dec; 23(18):1962-1969. PubMed ID: 27558979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipoprotein (a) in familial hypercholesterolaemia.
    Durrington PN; Bashir B; Bhatnagar D; Soran H
    Curr Opin Lipidol; 2022 Aug; 33(4):257-263. PubMed ID: 35942820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of Atherosclerotic Cardiovascular Disease in Children with Familial Hypercholesterolemia.
    Peterson AL; McNeal CJ; Wilson DP
    Curr Atheroscler Rep; 2021 Aug; 23(10):64. PubMed ID: 34453222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society.
    Cuchel M; Bruckert E; Ginsberg HN; Raal FJ; Santos RD; Hegele RA; Kuivenhoven JA; Nordestgaard BG; Descamps OS; Steinhagen-Thiessen E; Tybjærg-Hansen A; Watts GF; Averna M; Boileau C; Borén J; Catapano AL; Defesche JC; Hovingh GK; Humphries SE; Kovanen PT; Masana L; Pajukanta P; Parhofer KG; Ray KK; Stalenhoef AF; Stroes E; Taskinen MR; Wiegman A; Wiklund O; Chapman MJ;
    Eur Heart J; 2014 Aug; 35(32):2146-57. PubMed ID: 25053660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-coronary atherosclerotic cardiovascular disease in patients with familial hypercholesterolaemia.
    Anagnostis P; Vaitsi K; Mintziori G; Goulis DG; Mikhailidis DP
    Curr Med Res Opin; 2020 May; 36(5):731-740. PubMed ID: 32096673
    [No Abstract]   [Full Text] [Related]  

  • 17. A resilient type of familial hypercholesterolaemia: case-control follow-up of genetically characterized older patients in the SAFEHEART cohort.
    Pérez de Isla L; Watts GF; Muñiz-Grijalvo O; Díaz-Díaz JL; Alonso R; Zambón D; Fuentes-Jimenez F; Mauri M; Padró T; Vidal-Pardo JI; Barba MA; Ruiz-Pérez E; Michán A; Mediavilla JD; Hernandez AM; Romero-Jimenez MJ; Badimon L; Mata P;
    Eur J Prev Cardiol; 2022 May; 29(5):795-801. PubMed ID: 34864959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment gaps and mortality among patients with familial hypercholesterolemia and cardiovascular disease: a 4-year follow-up study.
    Shemesh E; Azaiza A; Zafrir B
    Eur J Prev Cardiol; 2021 Jul; 28(8):e21-e22. PubMed ID: 32539452
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical Implications of Monogenic Versus Polygenic Hypercholesterolemia: Long-Term Response to Treatment, Coronary Atherosclerosis Burden, and Cardiovascular Events.
    D'Erasmo L; Minicocci I; Di Costanzo A; Pigna G; Commodari D; Ceci F; Montali A; Brancato F; Stanca I; Nicolucci A; Ascione A; Galea N; Carbone I; Francone M; Maranghi M; Arca M
    J Am Heart Assoc; 2021 May; 10(9):e018932. PubMed ID: 33890476
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of European and US guidelines for familial hypercholesterolaemia.
    Reiner Ž
    Curr Opin Lipidol; 2015 Jun; 26(3):215-20. PubMed ID: 25943839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.